ADORA2B and neoplasm: These discrepancies may also involve tissue-specific receptor dimerization: Adora2b-Adora2a heterodimers in ovarian cancer blunt pro-tumor effects, while Adora2b homodimers predominate in GC and breast cancer, amplifying signaling (79, 89).